Sollievo Pharmaceuticals
OperatingSollievo Pharmaceuticals, Inc
Healthcare · San Juan Capistrano, CA · Founded 2018
Seeking to improve safety for healthcare staff with our first product, Proviza
Financials
FY2020–FY2023 · from SEC filings · hover any figure for its sourceFigures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Pre-money — the valuation set before each round’s money came inBlue bars are the pre-money valuation the company stated for a priced round.
Fundraising history
Team
4 people
Dr. Schultz has held progressively significant responsibilities in both scientific and executive management positions during his 40-year career in the pharmaceutical and medical device industries. His development and commercial experience range from oral, inhalation, and liquid dosage forms. As President of REVA Medical, he lead the company to the approval of Fantom, the first fully radiopaque drug-eluting bioresorbable coronary scaffold. His expertise in developing combination products, and proven ability to lead internal and external resources in the startup environment provides Sollievo with the practical and strategic leadership it needs to navigate the drug development and commercial processes.
During his 35-year career, Mr. Schineller has held executive positions, CMO, SVP, and CCO at major pharmaceutical companies, including Novartis, Abbott, and Pfizer. He co-founded Veras Pharmaceuticals where he was the CCO. Novartis acquired the Veras product line. Mr. Schineller's success in commercializing drug products makes him an ideal advisor to guide the company's marketing and commercial launch strategies to ensure the successful uptake of its lead product Proviza. With Sollievo, Peter works on average 1 hour per week and on an as-needed basis.
Experienced Senior Manager with a 30-year history of working in the Pharmaceutical industry. Strong professional skills in Business Development, Alliance Management, Licensing, CMC Outsourcing, Biotechnology, Drug Development, and Pharmaceutical Project Management. Steve is responsible for identifying, sourcing, and contract negotiations with potential manufacturing partners and suppliers. Steve has been working with Sollievo for the past year
Names and titles as disclosed on StartEngine, SEC Form C. Bios and photos come from the platform campaign page and may be out of date.
Reg CF annual-report compliance
Filed 2 of 4 annual reports (FY2022–FY2025)
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.